Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin M Joyce

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Journal of Investigative Dermatology|October 15, 2018
Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell TransplantationPeggy A Wu, Robert S Stern, Victor Huang, et al.
Acta Haematologica|February 14, 2015
Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplantJon E Arnason, Katarina Luptakova, Jacalyn Rosenblatt, et al.
Nuclear Medicine Communications|July 31, 2014
Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scansElisa Franquet, Mathew R Palmer, Anne E Gifford, et al.
Transfusion|May 1, 2024
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortalityZachary M Avigan, Ajoy L Dias, Laura E Dodge, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248Steven P Treon, Zachary R Hunter, Jeffrey Matous, et al.
Molecular Genetics & Genomic Medicine|October 6, 2015
Inherited CHST11/MIR3922 deletion is associated with a novel recessive syndrome presenting with skeletal malformation and malignant lymphoproliferative diseaseSameer S Chopra, Ignaty Leshchiner, Hatice Duzkale, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Journal of Investigative Dermatology|October 15, 2018
Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell TransplantationPeggy A Wu, Robert S Stern, Victor Huang, et al.
Acta Haematologica|February 14, 2015
Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplantJon E Arnason, Katarina Luptakova, Jacalyn Rosenblatt, et al.
Nuclear Medicine Communications|July 31, 2014
Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scansElisa Franquet, Mathew R Palmer, Anne E Gifford, et al.
Transfusion|May 1, 2024
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortalityZachary M Avigan, Ajoy L Dias, Laura E Dodge, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248Steven P Treon, Zachary R Hunter, Jeffrey Matous, et al.
Molecular Genetics & Genomic Medicine|October 6, 2015
Inherited CHST11/MIR3922 deletion is associated with a novel recessive syndrome presenting with skeletal malformation and malignant lymphoproliferative diseaseSameer S Chopra, Ignaty Leshchiner, Hatice Duzkale, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
The New England Journal of Medicine|December 2, 2011
Interleukin-2 and regulatory T cells in graft-versus-host diseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T Kim, et al.
Pageof 3